Skip to main content
. 2020 Jan 18;7(1):ofz541. doi: 10.1093/ofid/ofz541

Table 1.

Demographic and Clinical Characteristics of 232 Patients who Experienced Recurrent Clostridioides difficile Infection (Cases) and Patients who Did Not Experience Recurrent Clostridioides difficile Infection (Controls)

All Patients (n = 232) Patients With Community-Acquired or Community-Onset C. difficile Infection (n = 131)
Controls (n = 146) Cases (n = 86) P Value Controls (n = 88) Cases (n = 43) P Value
Sex, No. (%)
 Female 93 (63.7) 47 (54.7) 0.174 63 (71.6) 26 (67.9) 0.200
 Male 53 (36.6) 39 (45.4) 25 (28.4) 17 (39.5)
Mean (SD) age, y 56.1 (16.1) 57.8 (16.8) 0.463 53.7 (16.8) 58.2 (17.6) 0.164
Race, No. (%)
 White 107 (75.4) 67 (77.9) 0.832 66 (77.7) 32 (74.4) 0.196
 Black 30 (21.1) 17 (19.8) 16 (18.8) 9 (20.9)
 Asian 5 (3.6) 2 (2.3) 3 (3.5) 2 (4.7)
Ethnicity, No. (%)
 Non-Hispanic 138 (97.2) 82 (95.4) 0.466 82 (96.5) 41 (95.4) 0.757
 Hispanic 4 (2.8) 4 (3.5) 3 (3.5) 2 (4.7)
Median (IQR) length of stay among inpatients, d 9 (3–20) 8 (4–18) 0.943 3 (1–5) 4 (3–7) 0.198
Mean (SD) Charlson comorbidity index score 4.12 (2.71) 4.41 (2.74) 0.414 3.3 (2.6) 4.3 (3.0) 0.040
Experienced prior episodes of CDI within previous 5 y, No. (%) 9 (6.2) 15 (17.4) 0.003 7 (8.0) 7 (16.3) 0.148
Inflammatory bowel disease, No. (%) 22 (15.2) 15 (17.4) 0.649 20 (22.7) 11 (25.6) 0.718
Received antibiotics before CDI diagnosis, No. (%) 110 (78.0) 71 (82.6) 0.409 66 (76.7) 35 (81.4) 0.546
Gastric acid suppression, No. (%) 83 (57.2) 42 (48.8) 0.215 44 (50.0) 18 (41.9) 0.381
Immunosuppression, No. (%) 54 (37.2) 31 (36.1) 0.856 16 (29.1) 11 (28.2) 0.925
Additional hospitalization before index diagnosis/hospitalization, No. (%) 34 (23.5) 34 (39.5) 0.010 16 (18.2) 11 (25.6) 0.326
Additional hospitalization after index diagnosis/hospitalization, No. (%) 24 (17.0) 33 (38.4) 0.001 14 (15.9) 9 (20.9) 0.478
Pet ownership, No. (%) 73 (50.4) 39 (45.4) 0.4363 51 (58.0) 18 (41.9) 0.083

Abbreviations: CDI, Clostridioides difficile infection; IQR, interquartile range.